Last reviewed · How we verify
Poractant alfa instillation
Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function.
Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function. Used for Respiratory distress syndrome in premature infants, Acute respiratory distress syndrome (ARDS).
At a glance
| Generic name | Poractant alfa instillation |
|---|---|
| Sponsor | Poznan University of Medical Sciences |
| Drug class | Pulmonary surfactant replacement |
| Target | Pulmonary surfactant (lipid and protein complex) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Poractant alfa is derived from porcine lung tissue and contains the key surfactant proteins and lipids necessary for reducing surface tension in the alveoli. By restoring surfactant function, it improves lung compliance, reduces work of breathing, and prevents alveolar collapse, particularly in conditions characterized by surfactant deficiency or dysfunction.
Approved indications
- Respiratory distress syndrome in premature infants
- Acute respiratory distress syndrome (ARDS)
Common side effects
- Transient oxygen desaturation
- Bradycardia
- Reflux of instillate into endotracheal tube
- Pulmonary hemorrhage
Key clinical trials
- Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes (PHASE4)
- Prophylactic Minimally Invasive Surfactant Evaluation (PHASE4)
- Intratracheal Budesonide/Surfactant Prevents BPD (PHASE4)
- Comparison of INRECSURE and LISA in Preterm Neonates With RDS (NA)
- Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia (PHASE4)
- OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP (PHASE4)
- Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations (PHASE4)
- Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poractant alfa instillation CI brief — competitive landscape report
- Poractant alfa instillation updates RSS · CI watch RSS
- Poznan University of Medical Sciences portfolio CI